2 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow iNKT Cells: new trials by email Literature Review of iNKT Cells trials Research Report on iNKT Cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, TACE - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 2 | Recruiting | Beijing Gene Key Life Technology Co., Ltd | 48 | 2025-11-14 | 2026-08-17 |
| A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 1 | Active not recruiting | Beijing Gene Key Life Technology Co., Ltd | 6 | 2025-04-03 | 2026-07-20 |
| Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy iNKT Cells, PD-1, Regorafenib - Hepatocellular Carcinoma | Phase 2 | Unknown | Beijing YouAn Hospital | 84 | 2023-10-26 | 2024-01-16 |
| Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC iNKT cells, Human recombinated Interleukin-2, TAE/TACE - Hepatocellular Carcinoma | Phase 2 | Completed | Beijing YouAn Hospital | 60 | 2018-03-01 | 2024-10-08 |
| Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC iNKT cells, IL-2, Tegafur - Hepatocellular Carcinoma | Phase 1 | Completed | Beijing YouAn Hospital | 10 | 2017-04-01 | 2024-09-19 |
Beijing YouAn Hospital (3) · Beijing Gene Key Life Technology Co., Ltd (2)
China (5)
Jun Lu, Director (2) · Gaojun Teng, MD (1) · Jun Lu, MD. (1)